Aclaris Therapeutics (ACRS) EBT Margin: 2017-2025
Historic EBT Margin for Aclaris Therapeutics (ACRS) over the last 8 years, with Sep 2025 value amounting to -464.69%.
- Aclaris Therapeutics' EBT Margin fell 26956.00% to -464.69% in Q3 2025 from the same period last year, while for Sep 2025 it was -922.44%, marking a year-over-year decrease of 78113.00%. This contributed to the annual value of -705.48% for FY2024, which is 42115.00% down from last year.
- Latest data reveals that Aclaris Therapeutics reported EBT Margin of -464.69% as of Q3 2025, which was up 49.62% from -922.34% recorded in Q2 2025.
- In the past 5 years, Aclaris Therapeutics' EBT Margin registered a high of -10.57% during Q4 2023, and its lowest value of -1,702.25% during Q2 2023.
- Over the past 3 years, Aclaris Therapeutics' median EBT Margin value was -706.46% (recorded in 2024), while the average stood at -731.88%.
- Over the last 5 years, Aclaris Therapeutics' EBT Margin had its largest YoY gain of 130,507bps in 2024, and its largest YoY loss of 104,872bps in 2024.
- Aclaris Therapeutics' EBT Margin (Quarterly) stood at -1,525.18% in 2021, then skyrocketed by 115,012bps to -375.07% in 2022, then soared by 36,449bps to -10.57% in 2023, then tumbled by 104,872bps to -1,059.30% in 2024, then plummeted by 26,956bps to -464.69% in 2025.
- Its last three reported values are -464.69% in Q3 2025, -922.34% for Q2 2025, and -1,094.02% during Q1 2025.